Alexandre Lambert

Bristol-Myers Squibb (Belgium)

1

h-index

1

Publications

2,617

Citations

Publications

1 shown

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber , Sandra P. D’Angelo , David R. Minor +25 more

2015 The Lancet Oncology 2617 citations

Frequent Co-Authors

Jeffrey S. Weber

American Society of Clinical Oncology

Sandra P. D’Angelo

Cornell University

David R. Minor

Northern California Melanoma Center

F. Stephen Hodi

Dana-Farber Cancer Institute

Ralf Gutzmer

Medizinische Hochschule Hannover

Bart Neyns

Universitair Ziekenhuis Brussel

Researcher Info

h-index: 1
Publications: 1
Citations: 2,617
Institution: Bristol-Myers Squibb (Belgium)

External Links

Google Scholar

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.